

## Washington University School of Medicine Digital Commons@Becker

---

### Open Access Publications

---

2013

# Soluble oligomers are sufficient for transmission of a yeast prion but do not confer phenotype

Jennifer E. Dulle

*Washington University in St. Louis*

Rachel E. Bouttenot

*Washington University in St. Louis*

Lisa A. Underwood

*Washington University in St. Louis*

Heather L. true

*Washington University in St. Louis*

Follow this and additional works at: [http://digitalcommons.wustl.edu/open\\_access\\_pubs](http://digitalcommons.wustl.edu/open_access_pubs)

---

### Recommended Citation

Dulle, Jennifer E.; Bouttenot, Rachel E.; Underwood, Lisa A.; and true, Heather L., "Soluble oligomers are sufficient for transmission of a yeast prion but do not confer phenotype." *The Journal of Cell Biology*.203,2. 197-204. (2013).  
[http://digitalcommons.wustl.edu/open\\_access\\_pubs/1906](http://digitalcommons.wustl.edu/open_access_pubs/1906)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [engeszer@wustl.edu](mailto:engeszer@wustl.edu).

# Soluble oligomers are sufficient for transmission of a yeast prion but do not confer phenotype

Jennifer E. Dulle, Rachel E. Bouttenot, Lisa A. Underwood, and Heather L. True

Department of Cell Biology and Physiology, Washington University in St. Louis, St. Louis, MO 63110

**A**myloidogenic proteins aggregate through a self-templating mechanism that likely involves oligomeric or prefibrillar intermediates. For disease-associated amyloidogenic proteins, such intermediates have been suggested to be the primary cause of cellular toxicity. However, isolation and characterization of these oligomeric intermediates has proven difficult, sparking controversy over their biological relevance in disease pathology. Here, we describe an oligomeric species of a yeast prion protein in cells that is sufficient for prion transmission and infectivity. These oligomers differ from the classic prion aggregates in

that they are soluble and less resistant to SDS. We found that large, SDS-resistant aggregates were required for the prion phenotype but that soluble, more SDS-sensitive oligomers contained all the information necessary to transmit the prion conformation. Thus, we identified distinct functional requirements of two types of prion species for this endogenous epigenetic element. Furthermore, the nontoxic, self-replicating amyloid conformers of yeast prion proteins have again provided valuable insight into the mechanisms of amyloid formation and propagation in cells.

## Introduction

The amyloid hypothesis proposes that large, protease-resistant amyloid fibers underlie the toxicity associated with several neurodegenerative diseases (Caughey and Lansbury, 2003; Chiti and Dobson, 2006). A definitive link between the amyloid aggregate and toxicity and neurodegeneration has not been established (Haass and Selkoe, 2007). A recent alternative proposal posits that an intermediate in the amyloid pathway is the primary toxic agent, while the large, insoluble aggregates may sequester oligomers and perhaps aid in cell survival (Kirkitadze et al., 2002). Soluble oligomers of several amyloidogenic proteins including amyloid- $\beta$ , huntingtin,  $\alpha$ -synuclein, and PrP have been detected both from analysis of amyloid-forming recombinant proteins and in cell and mouse models (Lasmézas et al., 1997; Conway et al., 1998; Tzaban et al., 2002; Sánchez et al., 2003; Silveira et al., 2005; Lesné et al., 2006; Sajnani et al., 2012). These oligomers, characterized as putative intermediates in amyloid formation, encompass a variety of sizes and structures that cause toxicity when introduced into disease models (Klyubin et al., 2005; Silveira et al., 2005; Sajnani et al., 2012). Isolation of these dynamic, soluble oligomers has remained largely elusive and,

as such, investigation of their role in amyloid formation has proven challenging.

The yeast prion protein Sup35 forms self-perpetuating amyloid conformers that are transmissible and infectious (Patino et al., 1996; Paushkin et al., 1996; Serio et al., 2000). To propagate the [*PSI*<sup>+</sup>] prion, Sup35 aggregates must undergo remodeling by the chaperone Hsp104, which facilitates monomer addition by severing amyloid structures to generate transmissible species, or propagons (Chernoff et al., 1995; Kryndushkin et al., 2003; Shorter and Lindquist, 2006; Satpute-Krishnan et al., 2007). Until now, *in vivo* studies have primarily reported on the role of Hsp104 in aggregate fragmentation (Ness et al., 2002; Satpute-Krishnan et al., 2007). Interestingly, Hsp104 has also been shown to catalyze amyloid formation *in vitro*, specifically impacting the formation of amyloid oligomers (Shorter and Lindquist, 2004). Moreover, recent *in vitro* evidence identified Sup35 oligomers as intermediates during amyloid formation under some conditions (Ohhashi et al., 2010). Here, we identify soluble, more SDS-sensitive oligomers of Sup35 as prion propagons and show that Hsp104 plays a role in their maintenance.

Correspondence to Heather L. True: [heather.true@wustl.edu](mailto:heather.true@wustl.edu)

Abbreviations used in this paper: SD, synthetic defined media; SDD-AGE, semi-denaturing detergent-agarose gel electrophoresis; YPD, yeast extract peptone dextrose.

© 2013 Dulle et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons license (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

Supplemental Material can be found at:  
<http://jcb.rupress.org/content/suppl/2013/10/17/jcb.201307040.DC1.html>

## Results and discussion

We performed a screen to identify cellular changes that rescued cells from toxic overexpression of *SUP35* in  $[PSI^+]$  cells (Vishveshwara et al., 2009). As this toxicity is dependent on  $[PSI^+]$ , we expected to uncover factors that affected Sup35 aggregation. One mutation identified, *hsp104-R830S* in the C-terminal domain of Hsp104, caused  $[PSI^+]$  cells to appear phenotypically  $[psi^-]$  by a readout of translation termination efficiency of a reporter that is indicative of the functional, soluble state of Sup35 (Fig. 1 A). Fluorescent imaging showed that Sup35 in *hsp104-R830S* cells appeared diffuse (Fig. 1 B), and by semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE), only monomeric Sup35 was detected in *hsp104-R830S* cells (Fig. 1 C). Strikingly, mating *hsp104-R830S* cells that appeared  $[psi^-]$  to wild-type *HSP104*  $[psi^-]$  cells produced many diploids that were phenotypically  $[PSI^+]$ , as seen by increased nonsense suppression (Fig. S1). Furthermore, sporulation of these diploids produced two  $[PSI^+]$  and two  $[psi^-]$  haploid progeny (Fig. 1 D), thereby indicating that prion-competent propagons had been maintained in *hsp104-R830S* cells that resulted in cryptic  $[PSI^+]$  (phenotypically undetectable). Indeed, transformation of *hsp104-R830S* cell lysates into wild-type  $[psi^-]$  cells demonstrated that these propagons were infectious and produced  $[PSI^+]$  cells. Out of 1,154 cells transformed, 45 were  $[PSI^+]$  (3.9% infectivity). Control transformations of  $[psi^-]$  lysates into  $[psi^-]$  cells resulted in only red colonies. Of the thousands of red colonies resulting from these control transformations, over 400 were further analyzed and confirmed to be  $[psi^-]$ . Thus, the infectious propagon in *hsp104-R830S* cells is unable to cause observable nonsense suppression, but reestablishes and maintains the  $[PSI^+]$  phenotype in the presence of wild-type *HSP104*.

Hsp104 normally functions to disaggregate nonprion aggregates and promote cellular recovery from stress (Glover and Lindquist, 1998). Therefore, we tested the activity of the Hsp104-R830S mutant with other known substrates. Interestingly, the thermotolerance of *hsp104-R830S* cells resembled that of wild-type cells (Fig. 2 A). Moreover, *hsp104-R830S* cells efficiently resolubilized heat-aggregated luciferase (Fig. 2 B). Hsp104 threads substrates through a central channel as a mechanism of disaggregation (Tessarz et al., 2008). The Hsp104 variant, HAP, has been used to investigate threading activity by coupling Hsp104 to the ClpP protease so that threaded substrates are degraded, resulting in decreased viability (Tessarz et al., 2008). We created the HAP-R830S variant and found that the mutant maintained threading activity (Fig. 2 C). Hsp104 is an AAA+ ATPase. Mutations that inhibit ATP hydrolysis or hexamerization typically prevent  $[PSI^+]$  propagation (Glover and Lum, 2009). We purified Hsp104-R830S and measured a reduced initial rate of ATP hydrolysis of  $0.1659 \pm 0.0308 \text{ nmol P}_i \cdot \mu\text{g}^{-1} \cdot \text{min}^{-1}$ , as compared with the initial rate of wild-type Hsp104 of  $0.2975 \pm 0.412 \text{ nmol P}_i \cdot \mu\text{g}^{-1} \cdot \text{min}^{-1}$ , which is comparable to previously published data (Tkach and Glover, 2004). We next analyzed the distribution of Hsp104-R830S, relative to wild-type Hsp104, using glycerol gradients and size-exclusion chromatography. These analyses revealed that Hsp104-R830S forms unstable hexamers (Fig. 2 D and Fig. S2). Together, these data reveal

that the reduced activity of Hsp104-R830S impairs the maintenance of the  $[PSI^+]$  phenotype.

Next, we assessed the state of Sup35 in *hsp104-R830S* cryptic  $[PSI^+]$  cells. We first performed sedimentation analysis with *hsp104-R830S* cryptic  $[PSI^+]$  lysates and found that Sup35 was soluble (Fig. 3 A). Next, we subjected lysates of *hsp104-R830S* cryptic  $[PSI^+]$  and *HSP104*  $[psi^-]$  cells to sucrose gradient fractionation. Monomeric Sup35 in  $[psi^-]$  cells remained in the top fractions, while Sup35 from *hsp104-R830S* lysates was detected further down the gradient, demonstrating the existence of some oligomeric species (Fig. 3 B). To understand how these oligomers relate to the large SDS-resistant aggregates associated with the  $[PSI^+]$  phenotype, we created a system to examine the effect of *hsp104-R830S* on pre-existing Sup35 aggregates. We covered *hsp104-R830S* cryptic  $[PSI^+]$  with wild-type *HSP104* expressed from a glucose-repressible promoter such that cells grown in nonrepressing galactose allowed the propagation of  $[PSI^+]$  and maintained SDS-resistant aggregates (Fig. 3 C, Gal). We then shifted the cells to glucose to repress wild-type *HSP104* (Fig. S3 A) and performed SDD-AGE to monitor the effect of *hsp104-R830S* on SDS-resistant Sup35 aggregates. Within 12 h of wild-type *HSP104* repression, monomeric Sup35 was apparent in *hsp104-R830S* cells. Within 24 h, SDS-resistant aggregates had disappeared (Fig. 3 C). As expected, when *hsp104-R830S* pGAL-*HSP104* cells were switched from glucose back to galactose to de-repress wild-type *HSP104*, they became phenotypically  $[PSI^+]$  (Fig. S3 B). Therefore, despite the loss of SDS-resistant aggregates, the propagons remained. Thus, the large SDS-resistant Sup35 aggregates are not strictly required for transmission of the prion.

We therefore reasoned that a less stable subpopulation of Sup35 might be capable of prion transmission. Indeed, that the addition of SDS to Sup35 prion aggregates results in smaller SDS-resistant polymers suggests that some less SDS-resistant species exists within the large prion aggregates (Kryndushkin et al., 2003). We investigated whether the soluble oligomers in *hsp104-R830S* cryptic  $[PSI^+]$  cells were less resistant to SDS, as has been reported for another prion (Taneja et al., 2007). We again performed SDD-AGE on *hsp104-R830S* cryptic  $[PSI^+]$  lysates but decreased the SDS concentration, and only then did we observe the presence of oligomeric species (Fig. 3 D). To determine how these species related to prion propagons and the cryptic  $[PSI^+]$  phenotype, we repeated the wild-type *HSP104* repression time course with *hsp104-R830S* cells using a low-SDS SDD-AGE. We observed the maintenance of less SDS-resistant, oligomeric species throughout the time course (Fig. 3 E), suggesting that the soluble, less SDS-resistant oligomers are the transmissible propagons in *hsp104-R830S* cryptic  $[PSI^+]$  cells.

Although we observed the unstable, soluble oligomers in the absence of insoluble aggregates, it is likely that both species exist in wild-type cells, and the more SDS-sensitive, soluble oligomers are more readily detectable in cells lacking insoluble aggregates. Therefore, we separated the Sup35 species in both *hsp104-R830S* cryptic  $[PSI^+]$  and wild-type  $[PSI^+]$  cells by sucrose gradient and performed protein transformation to determine whether the soluble fractions contained infectious propagons. Both *hsp104-R830S* and *HSP104* cells contained soluble Sup35





Figure 1. *hsp104-R830S* propagates cryptic [PSI+]. (A) [PSI+], [psi-], and *hsp104-R830S* cells were spotted on media containing  $\text{CuSO}_4$  to induce toxic overexpression of Sup35, media lacking adenine (SD-Ade) to assess nonsense suppression of the premature stop codon in *ade1-14*, and rich media (YPD). (B) *HSP104* [PSI+] and *hsp104-R830S* cells containing pSup35NM-GFP were imaged by fluorescence microscopy. Bar, 10  $\mu\text{m}$ . (C) Western blot of an SDS-containing agarose gel (SDD-AGE) shows Sup35 aggregate status in lysates of indicated strains. This blot is one representative of three individual experiments. (D) An example of two tetrads where mating *hsp104-R830S* to [psi-] cells, both containing the *ade1-14* mutation, resulted in tetrads with two red (efficient translation termination, *hsp104-R830S*) and two light pink (increased nonsense suppression, [PSI+] *HSP104*) haploids.






**Figure 2. Analysis of Hsp104-R830S activity reveals the mechanism of altered activity.** (A) Growth on YPD plates of the strains heat-shocked at 50°C for times indicated. Untreated cells were spotted before heat shock. (B) *HSP104* (black), *hsp104-R830S* (red), and *hsp104Δ* (orange) cells expressing heat-aggregatable luciferase were heat-shocked at 44°C while blocking new protein synthesis. Luminescence during recovery at 30°C was plotted as a fraction of luminescence before heat shock. Error bars represent the SD. (C) *hsp104Δ* cells carrying pRS315*CUP1-ClpP*, covered by the indicated plasmids, were spotted on media containing  $\text{CuSO}_4$  to induce expression of ClpP. (D) Hsp104 (top) and Hsp104-R830S (bottom) incubated with and without ATP (red/black) separated on a glycerol gradient by ultracentrifugation. This is one representation of three individual experiments. The top of the gradient is fraction number 1. Fractions were analyzed by SDS-PAGE and Western blot. All experiments were repeated at least three times.

oligomers that were infectious to [*psi*-] cells (Fig. 4 A). Although much of the Sup35 species from wild-type lysates migrated to the bottom of the gradient (35% of the total Sup35 which correspond to 54% of the infectivity), there were highly infectious oligomers in wild-type [*PSI*+]<sup>+</sup> cells that did not migrate with the heavy-sedimenting aggregates. This soluble pool of Sup35 contains 46% of the infectivity in wild-type [*PSI*+]<sup>+</sup> lysates. Curiously, the high-molecular weight aggregates observed in *hsp104-R830S* cells were not very infectious, suggesting that these aggregates are not the same high-molecular weight aggregates present in wild-type [*PSI*+]<sup>+</sup> cells and are not efficient [*PSI*+]<sup>+</sup> propagons. We then performed a simple solubility assay to separate wild-type [*PSI*+]<sup>+</sup> lysates into soluble and insoluble fractions (see Fig. 3 A), and then performed infectivity assays and SDD-AGE analysis. Strikingly, we found much of the infectivity in the soluble fraction (32.8% of the total Sup35, which corresponds to 30% of the infectivity) from sedimentation analysis (Fig. 4 B). Additionally, by SDD-AGE, we found that there were no Sup35 oligomers resistant to 2% SDS in the soluble fraction (Fig. 4 C). As such, these data support our hypothesis that insoluble aggregates are not strictly required for prion transmission.


Propagons contain the variant-specific properties required for inheritance and propagation of distinct prion phenotypes (Tanaka et al., 2004; Satpute-Krishnan and Serio, 2005). Therefore, the soluble oligomers in *hsp104-R830S* cryptic [*PSI*+]<sup>+</sup> cells should retain the properties necessary to propagate the parental strong [*PSI*+]<sup>+</sup> phenotype. If *hsp104-R830S* altered the prion structure, instead of cryptic [*PSI*+]<sup>+</sup>, weakened nonsense suppression and enhanced mitotic loss could be expected. After crossing *hsp104-R830S* cryptic [*PSI*+]<sup>+</sup> cells to [*psi*-] cells, we compared the [*PSI*+]<sup>+</sup> meiotic progeny to the parental strong [*PSI*+]<sup>+</sup> variant used initially in the screen. We found that the [*PSI*+]<sup>+</sup> progeny were indeed strong [*PSI*+]<sup>+</sup> phenotypically (Fig. 4 D). We then performed SDD-AGE analysis of the resulting [*PSI*+]<sup>+</sup> haploids as compared with the strong [*PSI*+]<sup>+</sup> and a weak [*PSI*+]<sup>+</sup> variant (Derkatch et al., 1996; Kryndushkin et al., 2003; Bagriantsev and Liebman, 2004). The SDS-resistant Sup35 aggregates in the [*PSI*+]<sup>+</sup> progeny appear the same as strong [*PSI*+]<sup>+</sup> (Fig. 4 E). We also noted that all the [*PSI*+]<sup>+</sup> transformants from infection of *hsp104-R830S* lysates into [*psi*-] cells were strong [*PSI*+]<sup>+</sup>. Thus, *Hsp104-R830S* did not alter the properties of the original variant phenotypically or biochemically, suggesting that there was no change in prion structure.



**Figure 3. *hsp104-R830S* propagates SDS-sensitive soluble oligomers of Sup35.** (A) Ultracentrifugation separated lysates into total (T), soluble (S), and pellet (P) fractions. (B) Fractionation of [psi-] and *hsp104-R830S* cryptic [PSI+] lysates separated by a 3-h centrifugation through a linear sucrose gradient. (C) *Hsp104* and *hsp104-R830S* cells carrying p416GAL-*HSP104* grown in galactose were switched to glucose to repress p416GAL-*HSP104*, and p416GAL-*HSP104* was efficiently repressed by 12 h in glucose as shown by Western blot in an *hsp104Δ* control (Fig. S3). Aliquots were taken from galactose and between 12 and 72 h in glucose and subjected to SDD-AGE. The shift in aggregate distribution occurs when changing carbon sources. (D) Lysates of the indicated strains were analyzed by SDD-AGE. The *HSP104* [PSI+] and [psi-] and *hsp104-R830S* samples were incubated in sample buffer containing the indicated percentages of SDS. (E) Same as D, but samples were subjected to SDD-AGE containing 0.01% SDS. All experiments were repeated at least three times and protein molecular weight markers (kD) are indicated.

We have shown, for the first time, the presence of soluble, prion-competent, less SDS-resistant oligomers of Sup35 in vivo. The less SDS-resistant, soluble oligomers are sufficient for transmission of the prion conformation, but are not sufficient to produce the nonsense suppression phenotype associated with [PSI+]. We have also shown that the insoluble aggregates that characterize

[PSI+] cells are not required for prion transmission or infectivity. Furthermore, we have uncovered two novel features of yeast prion propagons. First, they can be more SDS sensitive, where previously only SDS-resistant aggregates of Sup35 were shown to be infectious (Bagriantsev et al., 2008). This sensitivity parallels the previously described PK-sensitive PrP species, which



**Figure 4. Soluble oligomeric [PSI<sup>+</sup>] propagons are infectious and maintain the prion variant structure.** (A) Fractions of [PSI<sup>+</sup>] and *hsp104-R830S* cryptic [PSI<sup>+</sup>] lysates separated on a linear sucrose gradient by a 22-h ultracentrifugation step were analyzed by Western blot and the amount of Sup35 (presented as the percent of soluble Sup35) in each fraction was quantified by ImageJ (National Institutes of Health) and is indicated below each fraction in the Western blot. Equal volumes of each fraction were transformed into [*psi*<sup>-</sup>] cells. The fraction of infected [PSI<sup>+</sup>] cells obtained from each gradient fraction is indicated for *hsp104-R830S* (black) and *HSP104* (gray) cells. The fraction of infected [PSI<sup>+</sup>] cells was generated by compiling the infectivity data from four (*HSP104*) or five (*hsp104-R830S*) separate sucrose gradients and transformations. Sup35 in *hsp104-R830S* lysates appears to be more susceptible to proteolysis and frequently shows degradation products. Protein molecular weight markers (kD) are indicated.

can also transmit the prion (Sajnani et al., 2012). Second, soluble oligomers were able to act as propagons in vivo. Oligomers of several amyloidogenic proteins have been described and can cause toxicity in the absence of large aggregates (Haass and Selkoe, 2007). Indeed, our data correlate well with previous reports that visible Sup35 aggregates are lost in the mother cell and yet the prion is faithfully propagated (Taguchi and Kawai-Noma, 2010). Perhaps the SDS-resistant, insoluble Sup35 aggregates function as a reservoir for the continued renewal of transmissible propagons. This role for SDS-resistant yeast prion aggregates mirrors the proposed role for amyloid aggregates as traps for oligomers (Kirkpatrick et al., 2002). As such, we clearly show separate functions of two distinct aggregate species that are structurally related components of the same prion propagation pathway. A mutant in *Hsp104* enabled us to initially tease out these species. We favor a model whereby the decreased activity of *hsp104-R830S* results in reduced fragmentation of aggregates, but our data do not exclude the possibility that *Hsp104* normally plays a role in generating the large insoluble aggregates.

The soluble oligomers that exist in many protein conformational disorders are challenging to characterize due to their dynamic and metastable nature. In addition, conflicting reports on the properties and structure of oligomers complicate the elucidation of the important oligomeric species (Haass and Selkoe, 2007). The properties and mechanisms associated with yeast prion propagons may be similar to those associated with amyloidogenic proteins involved in self-propagating protein conformational disorders. Therefore, investigating these features may lead to a better understanding of the function and structure of soluble, self-templating oligomers, as well as the role of amyloid in disease.

## Materials and methods

### Strains and yeast cultivation

The yeast strains used in this study are derivatives of *Saccharomyces cerevisiae* 74-D694 and were grown using standard culture techniques. YPD is rich yeast medium, whereas SD is synthetic medium lacking amino acids as needed to select for maintenance of plasmids or screen for a nonsense suppression phenotype (SD-Ade). The strain used in the screen, 74-D694 [PSI<sup>+</sup>] *can1Δ::MFA1pr-HIS3-MFa1p rLEU2 ade1-14 ura3-52 lys2Δ::KanMX4 pRS315CUP1-SUP35*, was transformed with 10 independent plasmid pools

(B) Total, soluble, and insoluble fractions of *HSP104* [PSI<sup>+</sup>] lysates from sedimentation analysis were transformed into [*psi*<sup>-</sup>] cells. The relative infectivity of the total, soluble, and insoluble fractions was calculated as above and is indicated. (Inset) A Western blot for Sup35 in total (T), soluble (S), and insoluble (I) fractions from one sedimentation assay in this experiment with protein molecular weight marker (kD). Of the thousands of red colonies resulting from transformation of the soluble and insoluble fractions from wild-type [*psi*<sup>-</sup>] cells as a negative control, further analysis verified that 48 from each fraction were [*psi*<sup>-</sup>] in each of three independent experiments. (C) Total (T), soluble (S), and insoluble (I) fractions of *HSP104* [PSI<sup>+</sup>] lysates from sedimentation analysis were analyzed by SDD-AGE. The soluble fraction is from the top of the supernatant to prevent contamination from the pellet. This experiment was repeated three times. (D) Two representative tetrads from the mating of *hsp104-R830S* cryptic [PSI<sup>+</sup>] to [*psi*<sup>-</sup>] were spotted on YPD (top) and SD-Ade plates (bottom) to assess the level of nonsense suppression. Strong [PSI<sup>+</sup>] (Control A), weak [PSI<sup>+</sup>] (Control B), and [*psi*<sup>-</sup>] (Control C) strains were spotted for reference. (E) The lysates of the four white haploids from the tetrads in C were analyzed by SDD-AGE and compared with strong (St) and weak (Wk) [PSI<sup>+</sup>] controls.



of the mini-transposon (3XHA/lacZ(mTn3)) mutagenized library (provided by M. Snyder, Stanford University, Stanford, CA) and selected on media containing 350  $\mu$ M copper sulfate to induce expression of *SUP35*. Candidates that rescued toxicity associated with increased expression of *SUP35* were passaged a second time on copper sulfate media and were examined for the effect on *[PSI<sup>+</sup>]* phenotypically by color and genetically by mating to unmutagenized 74-D694 *[PSI<sup>+</sup>]* and *[psi<sup>-</sup>]* isogenic strains. Several mutants, not linked to the transposon, were analyzed and determined to be in Hsp104 through genetic analysis. The mutant characterized here, *hsp104-R830S*, was recreated and these strains were used for further characterization. Phenotypic assays are based on the amount of functional Sup35 to terminate the premature stop codon in *ade1-14*, which results in the accumulation of a red-pigmented intermediate in the adenine biosynthesis pathway (Liebman and Derkatch, 1999).

#### SDD-AGE protein analysis

Cells were lysed by bead-beating in buffer A (25 mM Tris-HCl, pH 7.5, 50 mM KCl, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, 10% glycerol plus mini EDTA-free protease inhibitors [Roche], Aprotinin [Sigma-Aldrich], and PMSF [Sigma-Aldrich]). Samples were treated at room temperature for 7 min in sample buffer containing 2% SDS, then electrophoresed through a 0.1% SDS, 1.5% agarose gel. The gels were subjected to Western blot with anti-Sup35 antibody. The experiments done with lower SDS concentrations contained 0.01% SDS in the gel and between 0.05 and 0.1% SDS in the sample buffer, as indicated. Molecular weight markers were not used because nondenatured protein aggregates were being analyzed.

#### Fluorescence microscopy

Cells were transformed with pRS426CUP1-*SUP35NM-GFP* and grown in media lacking uracil. 50  $\mu$ M CuSO<sub>4</sub> was added to logarithmically growing cells and grown for 4 h to induce expression of *SUP35NM-GFP*. Images of cells expressing Sup35NM-GFP, in water and at room temperature, were captured on a microscope (Bmax-60F; Olympus) containing a 1.35 NA/100x UPlanApo objective lens, spinning disc Confocal Scanner Unit (CSU10), and an ICCD camera (XR-Mega10; Stanford Photonics). Images were acquired using QED software and analyzed by ImageJ (National Institutes of Health). In ImageJ, images were colored green for presentation.

#### Protein transformation

Recipient *[psi<sup>-</sup>]* cells from logarithmically growing cultures were spheroplasted with lyticase. Samples from cell lysis, sedimentation analysis, and sucrose gradient fractionation were added to the spheroplasts in 1 M sorbitol along with a vector containing the *URA3* gene for selection on media lacking uracil. The cells were incubated at room temperature then recovered at 30°C. Media containing glucose, sorbitol, and agar was added to the cells before plating on sorbitol plates lacking uracil. Transformants were replica plated to YPD plates, and individual colonies were picked from those YPD plates and spotted onto YPD and both media lacking adenine and containing GdHCl for quantification of infectivity.

#### Purification of Hsp104

Hsp104 was purified as described previously (Lum et al., 2004). Recombinant Hsp104 tagged with a 6x-Histidine tag was expressed in *Escherichia coli* cells and affinity purified using a Ni<sup>2+</sup>-Sephacrose column. Next, the 6x-Histidine tag was removed by cleavage with the TEV protease and the untagged Hsp104 was separated from the uncleaved, tagged Hsp104 by affinity purification. The untagged Hsp104 was further purified using anion exchange via a Q-Sepharose column. The pure Hsp104 collected from the Q-Sepharose column was then separated on an S-300 gel filtration column to isolate monomeric Hsp104. Purified, monomeric Hsp104 was pooled, concentrated, and frozen at -80°C. Multiple purification preparations were used for all assays in repeat experiments.

#### ATP hydrolysis assays

ATP hydrolysis was monitored by the Malachite Green assay. 2  $\mu$ g purified Hsp104 was equilibrated in buffer (40 mM Tris-HCl, pH 7.5, 175 mM NaCl, 5 mM MgCl<sub>2</sub>, and 0.02% Triton X-100) at 37°C before adding 5 mM ATP (Sigma-Aldrich). During incubation of Hsp104 with ATP at 37°C, samples were taken and free phosphate was measured by addition of Malachite Green dye (Sigma-Aldrich). Color development occurred over 1 min and was terminated by the addition of 3.4% citric acid (Sigma-Aldrich). Absorbance was measured at 650 nm.

#### Glycerol gradients

Purified protein at 75  $\mu$ g was incubated in buffer (20 mM Tris, pH 8, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 2 mM EDTA, and 10% glycerol)  $\pm$  ATP for

5 min on ice before loading onto linear glycerol gradients (15–35%). The gradients were spun at 34,000 rpm for 18 h in a rotor (SW55; Beckman Coulter). Gradients were fractionated and the fractions analyzed by SDS-PAGE and Western blot with anti-Hsp104 antibody.

#### Size-exclusion chromatography

Purified protein at 1 mg/ml was incubated in buffer (50 mM Tris, pH 7.5, 200 mM KCl, 10 mM MgCl<sub>2</sub>, 2 mM DTT, and 2 mM EDTA)  $\pm$  ATP for 5 min. The sample was applied to an S-300HR column (GE Healthcare) and fractions were collected. The concentration of Hsp104 was measured by Bradford analysis (Bio-Rad Laboratories).

#### Thermotolerance assays

Cells were grown to mid-log phase at 30°C. An equal number of cells from each sample were aliquoted and pretreated at 37°C for 30 min. Samples were heat shocked at 50°C for the indicated amounts of time and then diluted fivefold before plating onto solid rich medium.

#### In vivo luciferase refolding assay

In vivo luciferase refolding assays were performed as described previously (Tipton et al., 2008). In brief, cells carrying pRS316GPD-*Lux* (provided by B. Bukau, ZMBH, Ruprecht-Karls-Universität Heidelberg, Germany) were pretreated at 37°C for 1 h to induce expression of *HSP104*, then heat shocked at 44°C for 1 h. After 50 min of heat shock, cycloheximide was added to prevent new protein synthesis. After heat shock, the cells recovering at 30°C were aliquoted at 15-min intervals and D-luciferin (Sigma-Aldrich) was added. Luminescence was measured and plotted as a percentage of total luciferase activity before heat shock.

#### Hsp104 shutoff experiments

The diploid strains, *HSP104/hsp104 $\Delta$ ::leu2* and *HSP104/hsp104-R830S* were transformed with pRS416GAL-*HSP104*, sporulated, and dissected on CSM-Ura + 0.25% galactose + 2% raffinose. Low levels of galactose were used to avoid curing *[PSI<sup>+</sup>]* by overexpression of *HSP104*. Progeny were selected that contained the plasmid and were pink in color as evidence that *[PSI<sup>+</sup>]* was maintained. Cells were grown in CSM-Ura + 0.25% galactose + 2% raffinose for 48 h before switching the cells to glucose media lacking uracil to repress expression of the *HSP104* plasmid. At 6-h intervals, aliquots of the sample were taken and both pelleted for SDD-AGE and plated on CSM-Ura + 0.25% galactose + 2% raffinose plates. SDD-AGE was performed as described above. Gels were transferred to PVDF membrane and probed with anti-Sup35 antibody.

#### Sup35 solubility assays

Cells were lysed by bead-beating in buffer (10 mM NaPO<sub>4</sub>, pH 7.5, 250 mM NaCl, 2% SDS, 1% Triton X-100 plus mini EDTA-free protease inhibitors [Roche], and PMSF [Sigma-Aldrich]). Lysates were subjected to ultracentrifugation at 100,000 rpm in a rotor (TLA-100; Beckman Coulter) for 1 h. The supernatant was collected and the pellet resuspended in lysis buffer. Total, supernatant, and pellet fractions were subjected to SDS-PAGE and Western blot with anti-Sup35 antibody as well as protein transformation.

#### Sucrose gradients

Cells were lysed by bead-beating in buffer A. Total protein was normalized to 1 mg/ml and loaded onto a 4-ml linear sucrose gradient (15–60%) and centrifuged at 32,000 rpm for either 3 or 22 h. To compare infectivity of soluble and insoluble Sup35 from *HSP104 [PSI<sup>+</sup>]* by sucrose gradient, we increased the time of centrifugation to a time that reproducibly showed a large fraction of pelletable Sup35. Thus, after a 22-h spin, we are able to distinguish the soluble Sup35 and the insoluble Sup35 that migrates to the bottom of the gradient. Gradients were fractionated and the fractions were analyzed by SDS-PAGE, Western blot, and protein transformation.

#### Online supplemental material

Fig. S1 shows that the mating of *hsp104-R830S* cells to *HSP104 [psi<sup>-</sup>]* cells results in cells that are phenotypically *[PSI<sup>+</sup>]*. Fig. S2 shows that *Hsp104-R830S* forms unstable hexamers by size-exclusion chromatography. Fig. S3 A shows that growing the cells containing the pRS416-GAL-*HSP104* construct in glucose efficiently represses wild-type *HSP104* on the plasmid. Fig. S3 B shows that *hsp104-R830S* cells maintain *[PSI<sup>+</sup>]* propagons throughout the shutoff time course as de-repression of wild-type *HSP104* results in pink *[PSI<sup>+</sup>]* colonies. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201307040/DC1>.

We thank J.R. Glover, B. Bukau, and J. Weissman for generously providing plasmids and protocols; and J. Cooper for use of his confocal microscope.



We also thank members of the True laboratory and C. Wehl, A. Cashikar, O. Mooren, and D. Sanders for comments on the manuscript.

This work was supported by funding from the National Institutes of Health (grant GM072778) and the National Science Foundation.

The authors declare no competing financial interests.

Author contributions: The screen was performed by R.E. Bouttenot. J.E. Dulle, R.E. Bouttenot, and H.L. True designed the experiments. J.E. Dulle and R.E. Bouttenot carried out all the experiments except for the HAP-R830S experiments, which were carried out by L.A. Underwood. J.E. Dulle, R.E. Bouttenot, and H.L. True analyzed the data. J.E. Dulle and H.L. True wrote the manuscript.

Submitted: 8 July 2013

Accepted: 24 September 2013

## References

- Bagriantsev, S., and S.W. Liebman. 2004. Specificity of prion assembly in vivo. [PSI<sup>+</sup>] and [PIN<sup>+</sup>] form separate structures in yeast. *J. Biol. Chem.* 279:51042–51048. <http://dx.doi.org/10.1074/jbc.M410611200>
- Bagriantsev, S.N., E.O. Gracheva, J.E. Richmond, and S.W. Liebman. 2008. Variant-specific [PSI<sup>+</sup>] infection is transmitted by Sup35 polymers within [PSI<sup>+</sup>] aggregates with heterogeneous protein composition. *Mol. Biol. Cell.* 19:2433–2443. <http://dx.doi.org/10.1091/mbc.E08-01-0078>
- Caughey, B., and P.T. Lansbury. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu. Rev. Neurosci.* 26:267–298. <http://dx.doi.org/10.1146/annurev.neuro.26.010302.081142>
- Chernoff, Y.O., S.L. Lindquist, B. Ono, S.G. Inge-Vechtomov, and S.W. Liebman. 1995. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi<sup>+</sup>]. *Science.* 268:880–884. <http://dx.doi.org/10.1126/science.7754373>
- Chiti, F., and C.M. Dobson. 2006. Protein misfolding, functional amyloid, and human disease. *Annu. Rev. Biochem.* 75:333–366. <http://dx.doi.org/10.1146/annurev.biochem.75.101304.123901>
- Conway, K.A., J.D. Harper, and P.T. Lansbury. 1998. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. *Nat. Med.* 4:1318–1320. <http://dx.doi.org/10.1038/3311>
- Derkatch, I.L., Y.O. Chernoff, V.V. Kushnirov, S.G. Inge-Vechtomov, and S.W. Liebman. 1996. Genesis and variability of [PSI<sup>+</sup>] prion factors in *Saccharomyces cerevisiae*. *Genetics.* 144:1375–1386.
- Glover, J.R., and S. Lindquist. 1998. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. *Cell.* 94:73–82. [http://dx.doi.org/10.1016/S0092-8674\(00\)81223-4](http://dx.doi.org/10.1016/S0092-8674(00)81223-4)
- Glover, J.R., and R. Lum. 2009. Remodeling of protein aggregates by Hsp104. *Protein Pept. Lett.* 16:587–597. <http://dx.doi.org/10.2174/092986609788490087>
- Haass, C., and D.J. Selkoe. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat. Rev. Mol. Cell Biol.* 8:101–112. <http://dx.doi.org/10.1038/nrm2101>
- Kirkitadze, M.D., G. Bitan, and D.B. Teplow. 2002. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. *J. Neurosci. Res.* 69:567–577. <http://dx.doi.org/10.1002/jnr.10328>
- Klyubin, I., D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe, and M.J. Rowan. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. *Nat. Med.* 11:556–561. <http://dx.doi.org/10.1038/nm1234>
- Kryndushkin, D.S., I.M. Alexandrov, M.D. Ter-Avanesyan, and V.V. Kushnirov. 2003. Yeast [PSI<sup>+</sup>] prion aggregates are formed by small Sup35 polymers fragmented by Hsp104. *J. Biol. Chem.* 278:49636–49643. <http://dx.doi.org/10.1074/jbc.M307996200>
- Lasmézas, C.I., J.P. Deslys, O. Robain, A. Jaegly, V. Beringue, J.M. Peyrin, J.G. Fournier, J.J. Hauw, J. Rossier, and D. Dormont. 1997. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. *Science.* 275:402–405. <http://dx.doi.org/10.1126/science.275.5298.402>
- Lesné, S., M.T. Koh, L. Kotilinek, R. Kaye, C.G. Glabe, A. Yang, M. Gallagher, and K.H. Ashe. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature.* 440:352–357. <http://dx.doi.org/10.1038/nature04533>
- Liebman, S.W., and I.L. Derkatch. 1999. The yeast [PSI<sup>+</sup>] prion: making sense of nonsense. *J. Biol. Chem.* 274:1181–1184. <http://dx.doi.org/10.1074/jbc.274.3.1181>
- Lum, R., J.M. Tkach, E. Vierling, and J.R. Glover. 2004. Evidence for an unfolding/threading mechanism for protein disaggregation by *Saccharomyces cerevisiae* Hsp104. *J. Biol. Chem.* 279:29139–29146. <http://dx.doi.org/10.1074/jbc.M403777200>
- Ness, F., P. Ferreira, B.S. Cox, and M.F. Tuite. 2002. Guanidine hydrochloride inhibits the generation of prion “seeds” but not prion protein aggregation in yeast. *Mol. Cell. Biol.* 22:5593–5605. <http://dx.doi.org/10.1128/MCB.22.15.5593-5605.2002>
- Ohhashi, Y., K. Ito, B.H. Toyama, J.S. Weissman, and M. Tanaka. 2010. Differences in prion strain conformations result from non-native interactions in a nucleus. *Nat. Chem. Biol.* 6:225–230. <http://dx.doi.org/10.1038/nchembio.306>
- Patino, M.M., J.J. Liu, J.R. Glover, and S. Lindquist. 1996. Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. *Science.* 273:622–626. <http://dx.doi.org/10.1126/science.273.5275.622>
- Paushkin, S.V., V.V. Kushnirov, V.N. Smirnov, and M.D. Ter-Avanesyan. 1996. Propagation of the yeast prion-like [psi<sup>+</sup>] determinant is mediated by oligomerization of the SUP35-encoded polypeptide chain release factor. *EMBO J.* 15:3127–3134.
- Sajani, G., C.J. Silva, A. Ramos, M.A. Pastrana, B.C. Onisko, M.L. Erickson, E.M. Antaki, I. Dynin, E. Vázquez-Fernández, C.J. Sigurdson, et al. 2012. PK-sensitive PrP is infectious and shares basic structural features with PK-resistant PrP. *PLoS Pathog.* 8:e1002547. <http://dx.doi.org/10.1371/journal.ppat.1002547>
- Sánchez, I., C. Mähle, and J. Yuan. 2003. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. *Nature.* 421:373–379. <http://dx.doi.org/10.1038/nature01301>
- Satpute-Krishnan, P., and T.R. Serio. 2005. Prion protein remodeling confers an immediate phenotypic switch. *Nature.* 437:262–265. <http://dx.doi.org/10.1038/nature03981>
- Satpute-Krishnan, P., S.X. Langseth, and T.R. Serio. 2007. Hsp104-dependent remodeling of prion complexes mediates protein-only inheritance. *PLoS Biol.* 5:e24. <http://dx.doi.org/10.1371/journal.pbio.0050024>
- Serio, T.R., A.G. Cashikar, A.S. Kowal, G.J. Sawicki, J.J. Moslehi, L. Serpell, M.F. Arnsdorf, and S.L. Lindquist. 2000. Nucleated conformational conversion and the replication of conformational information by a prion determinant. *Science.* 289:1317–1321. <http://dx.doi.org/10.1126/science.289.5483.1317>
- Shorter, J., and S. Lindquist. 2004. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. *Science.* 304:1793–1797. <http://dx.doi.org/10.1126/science.1098007>
- Shorter, J., and S. Lindquist. 2006. Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. *Mol. Cell.* 23:425–438. <http://dx.doi.org/10.1016/j.molcel.2006.05.042>
- Silveira, J.R., G.J. Raymond, A.G. Hughson, R.E. Race, V.L. Sim, S.F. Hayes, and B. Caughey. 2005. The most infectious prion protein particles. *Nature.* 437:257–261. <http://dx.doi.org/10.1038/nature03989>
- Taguchi, H., and S. Kawai-Noma. 2010. Amyloid oligomers: diffuse oligomer-based transmission of yeast prions. *FEBS J.* 277:1359–1368. <http://dx.doi.org/10.1111/j.1742-4658.2010.07569.x>
- Tanaka, M., P. Chien, N. Naber, R. Cooke, and J.S. Weissman. 2004. Conformational variations in an infectious protein determine prion strain differences. *Nature.* 428:323–328. <http://dx.doi.org/10.1038/nature02392>
- Taneja, V., M.L. Maddelein, N. Talarek, S.J. Saube, and S.W. Liebman. 2007. A non-Q/N-rich prion domain of a foreign prion, [Het-s], can propagate as a prion in yeast. *Mol. Cell.* 27:67–77. <http://dx.doi.org/10.1016/j.molcel.2007.05.027>
- Tessarz, P., A. Mogk, and B. Bukau. 2008. Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. *Mol. Microbiol.* 68:87–97. <http://dx.doi.org/10.1111/j.1365-2958.2008.06135.x>
- Tipton, K.A., K.J. Verges, and J.S. Weissman. 2008. In vivo monitoring of the prion replication cycle reveals a critical role for Sis1 in delivering substrates to Hsp104. *Mol. Cell.* 32:584–591. <http://dx.doi.org/10.1016/j.molcel.2008.11.003>
- Tkach, J.M., and J.R. Glover. 2004. Amino acid substitutions in the C-terminal AAA+ module of Hsp104 prevent substrate recognition by disrupting oligomerization and cause high temperature inactivation. *J. Biol. Chem.* 279:35692–35701. <http://dx.doi.org/10.1074/jbc.M400782200>
- Tzaban, S., G. Friedlander, O. Schonberger, L. Horonchik, Y. Yedidia, G. Shaked, R. Gabizon, and A. Taraboulos. 2002. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. *Biochemistry.* 41:12868–12875. <http://dx.doi.org/10.1021/bi025958g>
- Vishveshwara, N., M.E. Bradley, and S.W. Liebman. 2009. Sequestration of essential proteins causes prion associated toxicity in yeast. *Mol. Microbiol.* 73:1101–1114. <http://dx.doi.org/10.1111/j.1365-2958.2009.06836.x>